Study of Enfuvirtide in HIV-Positive Subjects

Phase 1

Completed

• Conditions: HIV Infections; AIDS

• Registration Number: NCT00086710
• Lead Sponsor: Trimeris

Brief Summary

A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.

Detailed Description

Not available

Study Timeline

• Status Verified: 2004-04
• Study First Submitted: 2004-07-08
• Study First Submitted QC: 2004-07-12
• Study First Posted: 2004-07-13
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Exclusion Criteria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Trial Locations

Locations (1)

SFBC; 🇺🇸 Miami, Florida, United States